$SLS

Sellas Life Sciences (SLS) will present preclinical data for its drug SLS009 in pancreatic cancer at an upcoming conference. The company also expects Phase 2 trial results for AML in Q4 2026. SLS shares traded 0.5% higher. Analysts and investors are watching SLS009 and GPS for AML treatment potential. Retail sentiment remains bullish, with the stock up 211% in 2026.

SELLAS Life Sciences (SLS) will present preclinical data on SLS009 (tambiciclib) for pancreatic cancer at the 2026 AACR Conference. Three posters will showcase studies conducted with the University of Wisconsin, focusing on KRAS mutant models. SLS009 is a CDK9 inhibitor being developed for various cancer indications.

Sellas Life Sciences Group (SLS) stock rose 9% after a portfolio manager increased its stake by 32% ahead of a Phase 3 AML trial milestone. Commonwealth Equity Services now holds 38,470 shares. BlackRock owns 6.8% of SLS. CEO Stergiou expressed confidence in the Regal study's potential. The company seeks shareholder approval to expand its share reserve by 20 million shares.

BMF Reports argues SELLAS Life Sciences (SLS) is overvalued due to unclear Phase 3 trial data, predicting 76% downside if it fails. Fugazi Research claims TEN Holdings (XHLD) is a pump-and-dump scheme. A Value Investors’ Club author warns Charter Communications (CHTR) faces debt and competition risks. Notable executive departures include D-Wave Quantum (QBTS), Azenta (AZTA), Amrize (AMRZ), GE Vernova (GEV), and Tesla (TSLA).

Sellas Life Sciences (SLS) and ImmunityBio (IBRX) are gaining attention as the biotech sector performs strongly. The SPDR S&P Biotech ETF (XBI) is up 17% in June, with SLS surging 53% and IBRX gaining 10%. Analysts highlight opportunities in immuno-oncology and cancer treatments, citing potential M&A activity and FDA support for innovation.

U.S. stock indices fell Friday, with S&P 500 and Nasdaq ending the week lower as investors rotated out of tech and AI stocks. On Semiconductor (ON) announced a $7B acquisition, Sellas Lifesciences (SLS) saw record short interest, Infleqtion (INFQ) received an 'Outperform' rating, Nike (NKE) dropped on China concerns, and Apple (AAPL) fell 5% on demand worries. OpenAI may delay its IPO, sparking semiconductor selloff.

Sellas Life Sciences (SLS) shares fell 13.15% to $13.21 after concerns over its silence regarding a phase 3 clinical trial for its AML drug candidate, Galinpepimut-S. The company reported a 45.5% increase in Q2 losses to $9.6 million. Institutional investors boosted holdings by 490% to $79.7 million. The company hinted at a potential takeover through amended executive agreements.

U.S. stock futures fell Monday due to new Iran sanctions and U.S.-Canada trade tensions. Gold rose to $4,700/oz, while crude futures dropped 2% to $85.23/bbl. Nvidia (NVDA) plans hardware price hikes and a licensing deal. Alibaba (BABA) shares dropped 4% after a $10.2B equity raise. Applied Optoelectronics (AAOI) fell 13% on a $600M equity offering. SpaceX (SPCX) faces a 'Sell' rating from DZ Bank. Sellas Life Sciences (SLS) gained 2% on trial progress. Eli Lilly (LLY) launched its weight-manage

Sellas Life Sciences (SLS) shares dropped 9% on Monday, nearing a resistance zone of $15.45-$15.88 ahead of key AML trial data. The stock has rebounded 53% since a July low, with 27.2% of shares shorted. Investors await final results from the Phase 3 Regal study of Galinpepimut-S, with success defined as a 12.6-month median overall survival. SLS009, another AML drug, is also under focus. SLS is up 230% in 2026.

U.S. stock futures were mixed on Tuesday, with Nasdaq and Russell 2000 futures up 0.1%, Dow futures down 0.1%, and S&P 500 futures flat. Investors await July CPI data and geopolitical tensions impact sentiment. Key earnings reports include SMCI, CRWV, CAVA, LITE, and SLS. NVDA labeled AI data centers as investable assets, INTC upsized its share sale to $20B, and RIOT secured a $9.1B deal. RKLB shares fell despite a revenue beat, ASTS extended selloff, and SPCX faced lockup expiration pressures.